Home › Psoriasis › NCT07362017

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

A Multicenter, Open Label Study to Investigate the Safety and Efficacy of Ponesimod in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis

Who can join

Ages 18 to 65 · All sexes

Inclusion Criteria:

* Male and female subjects aged 18-65 years, inclusive
* BMI \>18 and \<40
* Minimum affected BSA of 10%
* PASI score ≥ 12
* PGA ≥ 3
* Diagnosed with moderate-to-severe plaque psoriasis

Exclusion Criteria:

* Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
* History of an allergic reaction or known and/or significant sensitivity to study drug

About the study

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

What is being tested

• Ponesimod (drug)

Sponsor: Vanda Pharmaceuticals · Participants: 300 · Started: Feb 17, 2026

Contact the study team

• Vanda Pharmaceuticals, Inc. · Phone: 202-734-3400

Official record on ClinicalTrials.gov — NCT07362017

Locations in the U.S.

Conditions

• Psoriasis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.